Business Description
Novartis AG
NAICS : 325412
ISIN : ARDEUT112521
Share Class Description:
BUE:NVS: CedearDescription
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.53 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | 1.35 | |||||
| Interest Coverage | 11.59 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.19 | |||||
| Beneish M-Score | -2.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.3 | |||||
| 3-Year EPS without NRI Growth Rate | 4.6 | |||||
| 3-Year FCF Growth Rate | 4.2 | |||||
| 3-Year Book Growth Rate | -3.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 7.18 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1.75 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.78 | |||||
| 9-Day RSI | 37.39 | |||||
| 14-Day RSI | 37.8 | |||||
| 6-1 Month Momentum % | 14.11 | |||||
| 12-1 Month Momentum % | 151.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.16 | |||||
| Quick Ratio | 0.93 | |||||
| Cash Ratio | 0.53 | |||||
| Days Inventory | 177.66 | |||||
| Days Sales Outstanding | 57.86 | |||||
| Days Payable | 125.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.29 | |||||
| Dividend Payout Ratio | 0.07 | |||||
| 3-Year Dividend Growth Rate | 3.8 | |||||
| Forward Dividend Yield % | 3.29 | |||||
| 5-Year Yield-on-Cost % | 3.58 | |||||
| 3-Year Average Share Buyback Ratio | 3.2 | |||||
| Shareholder Yield % | 10.63 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.72 | |||||
| Operating Margin % | 19.83 | |||||
| Net Margin % | 28.64 | |||||
| FCF Margin % | 23.48 | |||||
| ROE % | 29.19 | |||||
| ROA % | 13.1 | |||||
| ROIC % | 9.63 | |||||
| ROC (Joel Greenblatt) % | 88.08 | |||||
| ROCE % | 13.2 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.85 | |||||
| Forward PE Ratio | 2.01 | |||||
| PE Ratio without NRI | 23.14 | |||||
| Shiller PE Ratio | 16.36 | |||||
| Price-to-Owner-Earnings | 9.5 | |||||
| PS Ratio | 3.97 | |||||
| PB Ratio | 4.4 | |||||
| Price-to-Free-Cash-Flow | 17.5 | |||||
| Price-to-Operating-Cash-Flow | 13.96 | |||||
| EV-to-EBIT | 19.86 | |||||
| EV-to-Forward-EBIT | 13.37 | |||||
| EV-to-EBITDA | 10.87 | |||||
| EV-to-Forward-EBITDA | 10.63 | |||||
| EV-to-Revenue | 4.02 | |||||
| EV-to-Forward-Revenue | 4.11 | |||||
| EV-to-FCF | 17.74 | |||||
| Price-to-Projected-FCF | 1.31 | |||||
| Price-to-Median-PS-Value | 1.05 | |||||
| Earnings Yield (Greenblatt) % | 5.04 | |||||
| FCF Yield % | 6 | |||||
| Forward Rate of Return (Yacktman) % | 10.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novartis AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 14,436,611.955 | ||
| EPS (TTM) (ARS) | 4485.743 | ||
| Beta | 0 | ||
| Volatility % | 53.29 | ||
| 14-Day RSI | 37.8 | ||
| 14-Day ATR (ARS) | 457.847794 | ||
| 20-Day SMA (ARS) | 25421.425 | ||
| 12-1 Month Momentum % | 151.1 | ||
| 52-Week Range (ARS) | 10730.398851 - 35898 | ||
| Shares Outstanding (Mil) | 1,022.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis AG Stock Events
| Event | Date | Price(ARS) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novartis AG Frequently Asked Questions
What is Novartis AG(BUE:NVS)'s stock price today?
The current price of BUE:NVS is ARS25364.50. The 52 week high of BUE:NVS is ARS35898.00 and 52 week low is ARS10730.40.
When is next earnings date of Novartis AG(BUE:NVS)?
The next earnings date of Novartis AG(BUE:NVS) is 2024-04-23.
Does Novartis AG(BUE:NVS) pay dividends? If so, how much?
The Dividend Yield %  of Novartis AG(BUE:NVS) is 3.29% (As of Today), Highest Dividend Payout Ratio of Novartis AG(BUE:NVS) was 1.19. The lowest was 0.07. And the median was 0.85. The  Forward Dividend Yield % of Novartis AG(BUE:NVS) is 3.29%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers